Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma-Reference-Cited by-同舟云学术

Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma

Published:2017-02-06 Issue:2 Volume:12 Page:e0170078
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Cho Seulki,Lee Tae Sup,Song In Ho,Kim A-Ram,Lee Yoon-Jin,Kim Haejung,Hwang Haein,Jeong Mun Sik,Kang Seung Goo,Hong Hyo Jeong

Funder

the Korea Drug Development Fund (KDDF)

Kangwon National University

the Leaders INdustry-university Cooperation Project

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference31 articles.

1. Cholangiocarcinoma;SA Khan;Lancet,2005

2. Chemotherapy for cholangiocarcinoma: An update;N Ramirez-Merino;World J Gastrointest Oncol,2013

3. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer;T Okusaka;Cancer Chemother Pharmacol,2006

4. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study—The UK ABC-01 Study;JW Valle;Br J Cancer,2009

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Inhibition of Vessel Co-Option as an Emerging Strategy for Cancer Therapy;International Journal of Molecular Sciences;2024-01-11

2. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer;Gynecologic Oncology;2023-07

3. Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma;Cancers;2022-11-03

4. L1CAM expression as a predictor of platinum response in high‐risk endometrial carcinoma;International Journal of Cancer;2022-05-10

5. Inhibiting L1CAM Reverses Cisplatin Resistance of Triple Negative Breast Cancer Cells by Blocking AKT Signaling Pathway;Cancer Investigation;2022-01-18